GlassScriptPhysician profile
Earlando O Thomas
NPI 1205880911
$2,309.14
in general payments reported to CMS, 2019-2025
29 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $114 · 2021: $90.24 · 2022: $266 · 2023: $692 · 2024: $417 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995 · Education: $184 · Travel and Lodging: $87.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.47 |
| Education | $183.99 |
| Travel and Lodging | $87.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $254.05 | 2022-2023 | Desara |
| Astellas Pharma US INC | $248.07 | 2022-2023 | Veozah, Myrbetriq |
| Coloplast Corp | $237.82 | 2019 | |
| Mayne Pharma Commercial LLC | $202.21 | 2022-2024 | |
| Coopersurgical, INC. | $158.91 | 2019-2024 | Paragard T 380a, Summit Doppler |
| Medtronic, INC. | $142.95 | 2025 | Venaseal |
| Pfizer INC. | $127.98 | 2019-2024 | |
| Abbvie INC. | $108.44 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $95.64 | 2023-2024 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $74.73 | 2019-2023 | |
| Exact Sciences Corporation | $69.85 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $60.35 | 2024 | Wegovy |
| Therapeuticsmd, INC. | $57.99 | 2019 | |
| Lupin INC. | $55.97 | 2019-2020 | |
| Exeltis, USA INC. | $47.21 | 2023-2024 | Slynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $45.57 | 2019-2020 | |
| Hologic Sales and Service, LLC | $44.58 | 2024-2025 | Acessa Provu System, Accuprobe, Novasure |
| Smith+Nephew, INC. | $37.96 | 2023-2024 | Pico |
| Merck Sharp & Dohme LLC | $34.21 | 2019-2023 | Gardasil 9 |
| Organon LLC | $28.34 | 2024 | |
| Avion Pharmaceuticals | $26.64 | 2019-2020 | |
| Urovant Sciences INC | $24.83 | 2022 | |
| Allergan, INC. | $24.38 | 2019 | |
| Agile Therapeutics, INC. | $19.86 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.35 | 2021 | |
| Myovant Sciences INC. | $18.70 | 2022 | |
| Mission Pharmacal Company | $15.80 | 2019 | |
| Millicent US INC | $15.03 | 2024 | Femring, Intrarosa |
| Boston Scientific Corporation | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earlando Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.